Esophageal Cancer Clinical Trial
Official title:
Barrett's Oesophagus Two Yearly Surveillance Versus Endoscopy at Need: a Randomised Controlled Trial to Estimate Effectiveness and Cost-effectiveness Study (BOSS)
RATIONALE: Screening tests may help doctors find cancer cells early and plan better
treatment. It is not yet known whether endoscopy every 2 years is more effective than
endoscopy only as needed in finding esophageal cancer in patients with Barrett esophagus.
PURPOSE: This randomized phase III trial is studying endoscopy every 2 years to see how well
it works compared with endoscopy only as needed in monitoring patients with Barrett
esophagus.
OBJECTIVES:
Primary
- To establish whether endoscopic surveillance every 2 years or endoscopy at need only is
superior in terms of overall survival and, if neither is superior, whether endoscopy at
need only is non-inferior to surveillance every 2 years in patients with Barrett
esophagus.
Secondary
- To estimate the cost-effectiveness of endoscopic surveillance every 2 years as compared
to endoscopy at need only.
- To establish whether there is a significant difference between endoscopic surveillance
every 2 years or endoscopy at need only in terms of the incidence of esophageal cancer,
gastric or esophageal cancer, or all cancers.
- To establish whether there is a significant difference between endoscopic surveillance
every 2 years or endoscopy at need only in terms of the time to diagnosis of esophageal
adenocarcinoma.
- To establish whether there is a significant difference between endoscopic surveillance
every 2 years or endoscopy at need only in terms of the stage of esophageal
adenocarcinoma at diagnosis using TNM staging.
- To establish whether there is a significant difference between endoscopic surveillance
every 2 years or endoscopy at need only in terms of morbidity and mortality related to
endoscopy, esophageal surgery, and other endoscopy-related interventions (e.g.,
ablation).
- To establish whether there is a significant difference between endoscopic surveillance
every 2 years or endoscopy at need only in terms of the frequency of endoscopy.
OUTLINE: This is a multicenter study. Patients are stratified according to age at diagnosis
(< 65 years vs ≥ 65 years), length of Barrett metaplasia segment including tongues (< 2 cm vs
≥ 2 cm and ≤ 3 cm vs > 3 cm and ≤ 8 cm vs > 8 cm), and newly diagnosed disease (defined as
the date of endoscopy confirming Barrett metaplasia was within the past 4 months) (yes vs
no). Patients are randomized to 1 of 2 intervention arms.
- Arm I: Patients undergo surveillance endoscopy with quadrantic biopsies taken every 2
cm. Patients undergo endoscopy every 2 years for a total of 6 endoscopies over 10 years.
- Arm II: Patients undergo endoscopy as needed over 10 years. All patients may undergo
urgent endoscopy if they develop dysphagia, unexplained weight loss of > 7 lb,
iron-deficiency anemia, recurrent vomiting, or worsening upper gastrointestinal
symptoms.
All patients complete a questionnaire that includes a quality-of-life measure and questions
about medication at baseline, every 2 years, and following key events (e.g., diagnosis of any
cancer or high-grade dysplasia).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 |